Integra Lifesciences Holdings Corp (NASDAQ:IART) – Stock analysts at Piper Jaffray Companies dropped their Q1 2019 earnings per share estimates for Integra Lifesciences in a research report issued to clients and investors on Wednesday, October 31st. Piper Jaffray Companies analyst M. O’brien now expects that the life sciences company will post earnings per share of $0.63 for the quarter, down from their prior forecast of $0.65. Piper Jaffray Companies also issued estimates for Integra Lifesciences’ Q2 2019 earnings at $0.64 EPS and Q3 2019 earnings at $0.64 EPS.
A number of other brokerages have also recently issued reports on IART. Citigroup cut their price objective on Integra Lifesciences from $66.00 to $60.00 and set a “neutral” rating for the company in a report on Friday. JMP Securities cut their price objective on Integra Lifesciences from $66.00 to $62.00 and set a “market outperform” rating for the company in a report on Friday. Wells Fargo & Co cut their price objective on Integra Lifesciences from $61.00 to $55.00 and set a “market perform” rating for the company in a report on Thursday. Cantor Fitzgerald cut their price objective on Integra Lifesciences from $59.00 to $54.00 and set a “neutral” rating for the company in a report on Thursday. Finally, Oppenheimer reissued a “buy” rating and set a $70.00 price objective on shares of Integra Lifesciences in a report on Wednesday. One equities research analyst has rated the stock with a sell rating, eleven have assigned a hold rating and five have issued a buy rating to the company. Integra Lifesciences currently has an average rating of “Hold” and an average target price of $61.00.
Shares of IART stock opened at $53.66 on Friday. The firm has a market capitalization of $4.57 billion, a P/E ratio of 27.66, a PEG ratio of 1.66 and a beta of 0.76. Integra Lifesciences has a one year low of $45.96 and a one year high of $67.50. The company has a debt-to-equity ratio of 1.10, a current ratio of 3.52 and a quick ratio of 2.27.
Integra Lifesciences (NASDAQ:IART) last issued its earnings results on Wednesday, October 31st. The life sciences company reported $0.59 EPS for the quarter, hitting the consensus estimate of $0.59. The firm had revenue of $365.85 million during the quarter, compared to analysts’ expectations of $367.89 million. Integra Lifesciences had a return on equity of 18.01% and a net margin of 5.49%. Integra Lifesciences’s quarterly revenue was up 31.2% compared to the same quarter last year. During the same period last year, the business earned $0.45 earnings per share.
In other Integra Lifesciences news, major shareholder Richard E. Caruso sold 46,676 shares of Integra Lifesciences stock in a transaction on Wednesday, October 17th. The stock was sold at an average price of $63.19, for a total transaction of $2,949,456.44. Following the completion of the transaction, the insider now directly owns 134,134 shares of the company’s stock, valued at $8,475,927.46. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Jeffrey Mosebrook sold 1,000 shares of Integra Lifesciences stock in a transaction dated Friday, August 10th. The shares were sold at an average price of $62.42, for a total value of $62,420.00. Following the completion of the transaction, the insider now directly owns 3,085 shares of the company’s stock, valued at $192,565.70. The disclosure for this sale can be found here. Over the last three months, insiders have sold 56,592 shares of company stock valued at $3,573,584. Company insiders own 5.10% of the company’s stock.
Several institutional investors have recently added to or reduced their stakes in IART. Jane Street Group LLC bought a new position in shares of Integra Lifesciences in the first quarter valued at about $403,000. LPL Financial LLC raised its holdings in shares of Integra Lifesciences by 28.6% in the first quarter. LPL Financial LLC now owns 6,840 shares of the life sciences company’s stock valued at $376,000 after buying an additional 1,523 shares during the last quarter. Legal & General Group Plc raised its holdings in shares of Integra Lifesciences by 4.9% in the first quarter. Legal & General Group Plc now owns 134,162 shares of the life sciences company’s stock valued at $7,397,000 after buying an additional 6,235 shares during the last quarter. Xact Kapitalforvaltning AB raised its holdings in shares of Integra Lifesciences by 41.5% in the first quarter. Xact Kapitalforvaltning AB now owns 9,202 shares of the life sciences company’s stock valued at $509,000 after buying an additional 2,700 shares during the last quarter. Finally, Principal Financial Group Inc. raised its holdings in shares of Integra Lifesciences by 2.1% in the first quarter. Principal Financial Group Inc. now owns 494,735 shares of the life sciences company’s stock valued at $27,379,000 after buying an additional 10,388 shares during the last quarter. 84.33% of the stock is owned by institutional investors and hedge funds.
Integra Lifesciences Company Profile
Integra LifeSciences Holdings Corporation develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, orthopedics, and general surgery. The company operates in two segments, Codman Specialty Surgical, and Orthopedics and Tissue Technologies.
Further Reading: Fundamental Analysis – How It Helps Investors
Receive News & Ratings for Integra Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.